AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05944562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulmimetostat
Description: Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
Study NCT05057806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25MG will be administered orally once per day for 3 months
Study NCT05057806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered orally once per day for 3 months
Study NCT05585151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML
Description: Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
Study NCT05585151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive statin treatment
Description: Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
Study NCT06402760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM comprehensive treatment
Description: 1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted.
Study NCT06402760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: The treatment methods prescribed in the guidelines.
Study NCT04736953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus
Study NCT04736953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05814198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HALP score
Description: we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
Study NCT04890366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study NCT05517382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportED
Description: suicide prevention videogame
Study NCT05517382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: non-health related videogame
Study NCT05608109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol personalized normative feedback (APNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
Study NCT05608109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media personalized normative feedback (SMPNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
Study NCT05507255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation training
Description: Relaxation training in the form of deep breathing exercises
Study NCT05507255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Relaxation training in the form of deep breathing exercises
Study NCT05507255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An aerobic exercise program
Description: An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
Study NCT06447727 — intervention group
Intervention type: DRUG
Intervention: SIRT with Yttrium-90 Microspheres
Description: Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
Study NCT06447727 — intervention group
Intervention type: DRUG
Intervention: FOLFIRI and Bevacizumab
Description: FOLFIRI and Bevacizumab
Study NCT06213168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
Study NCT05857449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion
Study NCT05318612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermal Therapy (LITT)
Description: LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
Study NCT05318612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: A sample of tissue from the tumor is obtained to confirm the diagnosis.
Study NCT04862897 — intervention group
Intervention type: OTHER
Intervention: Patient-controlled admissions
Description: Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
Study NCT05751889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
Study NCT05751889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Health Education
Description: Reading materials regarding HCV and safe sexual practice.
Study NCT06239090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehacor-T
Description: During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
Study NCT06239090 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
Study NCT02823132 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Study NCT04718948 — intervention group
Intervention type: DEVICE
Intervention: Urinary Multimodal Fiber Optic Spectroscopy
Description: Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device
Study NCT04718948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Cytology
Description: An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
Study NCT04718948 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
Study NCT06213168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP and HFNC
Description: Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
Study NCT04711408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California a head-mounted displa
Description: For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins.
Study NCT00041171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum
Study NCT00041171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT05412355 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
Study NCT05202366 — intervention group
Intervention type: DRUG
Intervention: CGB-400 Topical Gel
Description: CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
Study NCT06002035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Binom Vitamin D drops
Description: Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
Study NCT00041171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT05689073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conversational AI system
Description: The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
Study NCT05689073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational Brochure
Description: A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
Study NCT02497638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
Study NCT05481346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidomain training
Description: The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members.
Study NCT02497638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg once daily until progression.
Study NCT02497638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corresponding to metformin)
Description: One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
Study NCT04766385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study NCT04962607 — intervention group
Intervention type: OTHER
Intervention: Neo-Putty® as dressing agents in pulpotomized primary molars
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM
Study NCT02497638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corresponding to atorvastatin)
Description: One placebo tablet (corresponding to atorvastatin) once daily until progression.
Study NCT05092984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Study NCT06366542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
Study NCT06366542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
Study NCT06366542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercises
Description: The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
Study NCT06366542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optokinetic Stimulation exercises
Description: Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
Study NCT06366542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Stimulation exercises
Description: Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
Study NCT06375642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab, Surufatinib and HAIC
Study NCT04943458 — intervention group
Intervention type: OTHER
Intervention: Monitoring of cerebral autoregulation
Description: Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
Study NCT06247228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click2Move
Description: One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
Study NCT05429645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: setting up of the pace maker
Description: Setting up of a pace maker using a 3-dimensional (3D) guidance technique
Study NCT05092984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Ubrogepant
Description: Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Rimegepant
Description: Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Atogepant
Description: Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Eptinezumab
Description: Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Fremanezumab
Description: Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Galcanezumab
Description: Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Erenumab
Description: Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study NCT06212661 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin A
Description: Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Study NCT05380115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: weekly one on one video or telephone interviews with a study coach
Study NCT05850624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice massage
Description: active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
Study NCT05850624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality animation
Description: cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
Study NCT04730206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: 100 milligram tablets
Study NCT04730206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets, identical in size and shape
Study NCT04730206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: 200 milligram tablets
Study NCT04758819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)
Description: In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
Study NCT04368819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Study NCT04368819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Study NCT04520932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
Study NCT05485298 — intervention group
Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.